Navigation Links
Lead Trial Attorney in Clark County Hepatitis C Trial, Robert Eglet, Asks Jury to Award $10 Million Compensatory Damages for Anne Arnold, $2.5 Million for James Arnold
Date:10/6/2011

LAS VEGAS, Oct. 6, 2011 /PRNewswire/ -- This is being released by SCM:

(Photo:  http://photos.prnewswire.com/prnh/20111006/LA81891)

After 7 weeks of testimony and 4 hours of closing statements, lead trial attorney for the plaintiffs in the hepatitis C trial in Clark County Nevada, Robert Eglet, asked jurors to bring a verdict of $10 million in compensatory damages for Anne Arnold, $2.5 million in compensatory damages for James Arnold and to consider whether the Arnolds should receive punitive damages. 

Attorney Robert Eglet told jurors, corporate greed dictated the actions of the drug company Teva Pharmaceuticals. "The primary concern should be the safety of the patient. A responsible drug company should design, package and market the drug to reduce human error. The drug companies knew there was a problem with the jumbo infusion 50mL vials of Propofol in these endoscopy centers," said Eglet.

Eglet told jurors that every 50mL vial of Propofol was sent to the endoscopy centers with a vent spike labeled for multi dosing.  "The temptation and opportunity is too great for misuse and the drug company knew this. They took no steps to prevent this. They did nothing and Teva expert witnesses Craig Lea and Rosalie Lowe in depositions agreed that health care providers using 50mL vials in an endoscopy center create more of a proclivity to multi dose," said Eglet.  

Attorney Robert Eglet told the jury that production of the sedative Propofol was stopped within 3 weeks of the unprecedented $500 million verdict in the Chanin trial in May 2010. Teva Vice President, Craig Lea admitted under examination by Eglet that Teva turned the lights out in their Propofol plant 21 days after last year's verdict. 

The jury is now in deliberation.

Plaintiff Anne Arnold was exposed to the virus hepatitis C when a contaminated jumbo 50mL infusion vial of the anesthesia medication Propofol was reused during a colonoscopy procedure at the Endoscopy Center of Southern Nevada on July 13, 2007. The lawsuit filed by Mainor Eglet alleges design defect, breach of implied warranty for a particular purpose, failure to properly warn by sending a Dear Health Care Professional letter and duty to monitor.


'/>"/>
SOURCE SCM
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: ... data solutions, today announced that its MyDario product is expected to appear ... listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The ... ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
Breaking Medicine News(10 mins):